Holen Sie sich die Stockscreener-App
26.27
1.68%
-0.45
Handel nachbörslich:
25.79
-0.48
-1.83%
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer - Sahm
Edmond DE Rothschild Holding S.A. Invests $2.18 Million in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Deep Track Capital, LP Expands Nurix Therapeutics Inc (NRIX) Sta - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History - Yahoo Finance
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
Nurix Therapeutics, Inc. Announces Appointment of Wes Burwell to Chief Human Resources Officer - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Nurix (NRIX) Results Review: The EPS Result Is Below Expectation for the Current Session; Post-Earnings: Shares Fall 0.88%EPS Growth Rate - Vinanet
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right? - Sahm
Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche - Sahm
Nurix Therapeutics stock hits 52-week high at $26.40 By Investing.com - Investing.com Nigeria
Nurix Therapeutics stock hits 52-week high at $26.40 - Investing.com
Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Understanding the Setup: (NRIX) and Scalable Risk - Stock Traders Daily
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
NRIX Maintained by RBC Capital -- Price Target Raised to $36 - GuruFocus
Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - MarketBeat
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says - marketscreener.com
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $36 - Moomoo
RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating - marketscreener.com
Dimensional Fund Advisors LP Purchases 349,710 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Nurix Therapeutics, Inc. (NRIX): A Biotech Stock with 32% Upside Potential and Strong Buy Ratings - DirectorsTalk Interviews
Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 4,356 Shares of Stock - MarketBeat
Nurix Therapeutics stock hits 52-week high at $25.22 By Investing.com - Investing.com UK
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins - Yahoo Finance
NRIX (NRIX) holder Hansen details option exercise and 10b5-1 stock sales - Stock Titan
Nurix Therapeutics stock hits 52-week high at $25.22 - Investing.com
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighStill a Buy? - marketbeat.com
Nurix Therapeutics (NRIX) Chief Scientific Officer Gwenn Hansen Sells 4,111 Shares - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,111 Shares - MarketBeat
Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Options Chain - Yahoo! Finance Canada
NRIX (NRIX) holder files to sell 4,761 shares after recent 10b5-1 sales - Stock Titan
NRIX (NASDAQ: NRIX) insider files to sell 4,111 shares and details 10b5-1 trades - stocktitan.net
NRIX Looks 273.5% Overvalued on GF Value™ - GuruFocus
Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC - marketbeat.com
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader - The Manila Times
Nurix Therapeutics, Inc. Announces $10 Million Milestone Payment Associated with Initiation of A Phase 1 Clinical Trial of A Stat6 Degrader - marketscreener.com
Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial - marketscreener.com
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Form 4 Nurix Therapeutics Inc For: 4 August By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Christine Ring sells $382k stock - Investing.com
Roche, Nurix Therapeutics Enroll First Patient in Late-stage Study of Blood Cancer Drug Bexobrutideg - marketscreener.com
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - The Manila Times
Nurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLL - quiverquant.com
Nurix Therapeutics (NRIX) insider plans $385K sale of stock options and RSUs - stocktitan.net
Nurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - Stock Titan
Perceptive Advisors LLC Has $57.52 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,847 Shares of Stock - MarketBeat
Nurix therapeutics CSO Gwenn Hansen sells $89,953 in stock By Investing.com - Investing.com Nigeria
Nurix therapeutics CFO Hans van Houte sells $66,524 in shares By Investing.com - Investing.com Nigeria
Form 4 Nurix Therapeutics Inc For: 30 July By Investing.com - Investing.com Canada
Stempoint Capital LP Makes New $4.89 Million Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX is Redmile Group LLC's 5th Largest Position - MarketBeat
Nurix Therapeutics Inc (NRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nurix Therapeutics Inc (NRIX) Institutional Confidence - TradingKey
Nurix Therapeutics Inc (NRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):